Welcome to our dedicated page for HYPERFINE news (Ticker: HYPR), a resource for investors and traders seeking the latest updates and insights on HYPERFINE stock.
Hyperfine Inc (HYPR) pioneers accessible MRI technology through its groundbreaking Swoop® Portable MR Imaging System, transforming diagnostic capabilities in critical care and underserved settings. This page serves as the definitive source for verified news and announcements related to corporate developments, clinical milestones, and financial performance.
Investors and healthcare professionals will find timely updates on regulatory clearances, partnership agreements, quarterly earnings, and technological advancements. Our curated collection includes press releases about device deployments, peer-reviewed study results, and strategic initiatives driving portable MRI adoption.
Key coverage areas include Swoop system innovations, financial results analysis, leadership updates, and market expansion efforts. All content is rigorously verified to ensure accuracy and relevance for stakeholders evaluating HYPR's position in the medical imaging sector.
Bookmark this page for streamlined access to Hyperfine's latest progress in redefining bedside diagnostics through ultra-low-field MRI technology. Check regularly for objective reporting on developments impacting both clinical practice and long-term corporate strategy.
Hyperfine (Nasdaq: HYPR) has announced a strategic collaboration with NVIDIA to enhance its AI-powered portable MRI technology. The partnership focuses on advancing the Swoop® system, the first FDA-cleared AI-powered portable magnetic resonance brain imaging system.
The collaboration aims to leverage NVIDIA's AI expertise and accelerated computing to make brain MRI faster, smarter, and more affordable globally. Using NVIDIA's advanced suite of training and inference tools, including NVIDIA DALI and MONAI, the partnership will work on improving image quality, reducing scan times, and enabling faster diagnoses.
This initiative addresses a critical healthcare gap, as 90% of the global population lacks access to timely MRI diagnostics due to conventional MRI systems' high costs and infrastructure requirements. The Swoop® system is designed for point-of-care use in professional healthcare settings by trained clinicians, targeting the over three billion people worldwide affected by brain diseases.
Hyperfine (Nasdaq: HYPR), creator of the first FDA-cleared portable magnetic resonance brain imaging system—the Swoop® system, has scheduled its fourth quarter and full year 2024 financial results announcement for March 17, 2025. The company will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on the same day. Investors can access both the live audio webcast and recording through the company's investor relations website.
Hyperfine (NASDAQ: HYPR) has announced a $6.0 million registered direct offering through the sale of 4,511,278 shares of Class A common stock and accompanying warrants. Each share and warrant combination is priced at $1.33, with warrants exercisable immediately at $1.33 per share and expiring in five years.
Lake Street Capital Markets is serving as the exclusive placement agent. The offering is expected to close around February 12, 2025, subject to customary conditions. The company plans to use the proceeds for working capital and general corporate purposes, including commercial, manufacturing, and R&D activities.
The securities are being offered through an effective shelf registration statement on Form S-3 previously filed with the SEC on November 9, 2023 and declared effective on November 22, 2023.
Hyperfine (NASDAQ: HYPR) presented two significant studies at the 2025 International Stroke Conference demonstrating the effectiveness of their Swoop® system, an AI-powered portable MR brain imaging system, in stroke diagnosis. The ACTION PMR study, conducted across four leading institutions in the US and Europe, showed that physicians using Swoop® system images could diagnose 90% of acute infarcts compared to conventional high-field MRI.
Research from Ohio State University and Massachusetts General Hospital demonstrated the system's ability to differentiate between stroke and stroke mimics, with strong agreement to high-field MRI results. The study highlighted faster time-to-scan compared to conventional MRI and good specificity in emergency stroke care. The ACTION PMR study, which began in July 2023, included one hundred patients and has shown substantial agreement between Swoop® system diagnoses and standard-of-care imaging in detecting acute ischemic strokes.
Hyperfine (NASDAQ: HYPR) announced expansion of its commercial operations through new distribution agreements in Turkey, Israel, and Saudi Arabia for its Swoop® system, the first FDA-cleared AI-powered portable MR brain imaging system. These partnerships follow earlier 2024 agreements covering thirteen European markets, India, Malaysia, and Indonesia.
The company received CE approval in Europe for its ninth-generation AI-powered software in October 2024. The expansion targets regions with large populations and low MRI penetration, positioning Hyperfine for significant growth in 2025. The Swoop® system's portability and cost-effectiveness aim to address healthcare gaps in remote and emergency settings.
Hyperfine (NASDAQ: HYPR) showcased eleven clinical studies at RSNA 2024 demonstrating the effectiveness of their Swoop® system, an FDA-cleared AI-powered portable MR brain imaging system. The presentations highlighted the system's applications in stroke diagnosis, intracerebral hemorrhage monitoring, and multiple sclerosis imaging.
Washington University School of Medicine presented the largest study to date, analyzing over 350 exams in acute neurological care settings. The ACTION PMR study, involving multiple institutions including Massachusetts General Brigham and Ohio State Hospitals, evaluated the system's accuracy in detecting acute ischemic stroke, demonstrating promising results for hyperacute stroke detection and potential to increase MRI accessibility.
Hyperfine (Nasdaq: HYPR) announced the appointment of Chi Nguyen as VP of Office Strategy and Partnerships and Rafael Donnay as VP of Hospital Strategy and Health Economics. These roles aim to drive the adoption of the Swoop® system in hospitals and neurology offices, targeting significant growth in 2025 and beyond. Nguyen will lead office strategy, leveraging new MRI standards for CMS reimbursement, targeting 2,400 U.S. neurology offices. Donnay will focus on hospital strategy, aiming to integrate the Swoop® system into 9,600 U.S. sites, including critical care units and emergency departments. Additionally, Hyperfine plans international expansion, supported by recent CE approval for European markets. CEO Maria Sainz highlighted the strategic importance of these appointments for Hyperfine's growth and market development.
Hyperfine (Nasdaq: HYPR) announces that the Intersocietal Accreditation Commission (IAC) has issued new MRI standards that now include portable MR scanning at point of care. This update enables IAC-accredited facilities to qualify for CMS reimbursement for brain scans performed using the Swoop® system. The Swoop® Portable MR Imaging® system operates at 0.064T ultra-low field strength, eliminating the need for shielded MRI rooms, and features plug-and-scan functionality with a tablet interface for easy operation in any healthcare setting.
Hyperfine (Nasdaq: HYPR) announced that ten scientific abstracts featuring ultra-low-field imaging will be presented at the Radiological Society of North America (RSNA) 2024 Annual Meeting in Chicago. This represents the company's largest number of RSNA presentations to date, demonstrating growing interest in the Swoop® Portable MR Imaging® System. The abstracts cover diverse applications including emergency department workflow, neuro ICU implementation, intracerebral hemorrhage monitoring, acute ischemic stroke detection, and advanced imaging techniques for multiple sclerosis. The presentations highlight the system's versatility across multiple care settings and its potential to transform brain imaging and enhance patient care.
Hyperfine (Nasdaq: HYPR), creator of the first FDA-cleared portable magnetic resonance brain imaging system - the Swoop® system, has announced its participation in two upcoming investor conferences. The company will present at the BTIG Digital Health Forum on November 25, 2024, and the Mizuho Healthcare Conference in New York on December 11, 2024. Interested parties can schedule one-on-one meetings with management through their BTIG or Mizuho representatives.
FAQ
What is the current stock price of HYPERFINE (HYPR)?
What is the market cap of HYPERFINE (HYPR)?
